Interviews

Guillermo Novo

2026-04-12

What customers want is something that works better. It doesn’t matter whether it’s synthetic or not — if it performs better and meets the criteria, that’s what matters.

Bettina Hamelin

President

Innovative Medicines Canada (IMC)

2026-04-10

Our goal is to decrease the time to patient by at least a year. There is also a major opportunity to ensure that the Canadian government recognizes the importance of the life sciences sector, the importance of being ambitious for the sector, and the importance of investing more in innovative medicines.

Ying Huang,

CEO

Legend Biotech

2026-04-10

The key message is that treating patients earlier leads to greater clinical benefit. Using Carvykti earlier in the disease course allows patients to derive more durable responses and better outcomes than waiting until later lines of therapy.

Dr. M. S. N. Reddy

CEO

MSN Laboratories

2026-04-10

MSN is a very aggressive company, and we want to grow very aggressively in the global market in the generic space. Our goal is to develop, produce, and supply cost-effective medicines to society and expand our contribution through that model.

Sami Inkinen

Co-Founder & CEO

Virta Health

2026-04-10

If you change what people eat in the right way, and support them properly, you can eliminate hunger and cravings and reverse metabolic disease at scale.

Marko Rosa

CEO

Health Thru Nutrition (HTN)

2026-04-10

Prevention is everything. Supplements can’t replace lifestyle—they complement it.

William F. Tate IV

President

Rutgers University

2026-04-08

We want to incubate that talent and give people great opportunities to flourish. In 10 years, this county will be seen as one of the most important places for biomedical science in the country, and arguably in the world.

Deborah Waterhouse

CEO

ViiV Healthcare

2026-04-08

Over the next 20 years, our job is to keep improving treatment and prevention with longer-acting medicines, because that is one of the best ways to help end the epidemic. But beyond that, we are also making a significant investment in cure research.

Joseph Payne

CEO

Arcturus Therapeutics

2026-04-08

The mRNA field is at a turning point—moving beyond infectious disease vaccines into broader therapeutic applications.

Ray Chen

President of GenScript Life Science Group

GenScript

2026-04-07

Our new tagline, “Scripting Possibilities,” reflects the idea that many things once seen as impossible are now possible, and it is our job to make them happen.

Pagina 1 din 219